Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive its first coronavirus patient has been dosed in a Phase 3 trial of its drug lenzilumab.
Durrant says the now ongoing trial is the first randomized, double-blind, placebo-controlled, multi-center, Phase 3 study of an anti-GM-CSF conducted in the US.
Price: - -
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...
Industry & services
Retail & consumer
Health
Industry & services
Prev article
